T. Cluzeau

Interest of luspatercept in treatment of anemia in lower-risk of myelodysplastic syndrome anemia: a single center study of 26 patients

Myelodysplastic syndromes (MDS) are heterogeneous clonal hematological disorders characterized by ineffective hematopoiesis resulting in peripheral cytopenias. Luspatercept, an erythroid maturation agent, represents a novel therapeutic option for the management of anemia associat...